FTC challenges more than 100 drug patents owned by AbbVie, AstraZeneca, Boehringer and seven others
The Federal Trade Commission on Tuesday challenged more than 100 patents as improperly or inaccurately listed in the FDA’s Orange Book of generic drugs.
The patents, held by AbbVie, AstraZeneca, Boehringer Ingelheim, GSK, Teva and five other manufacturers, cover expensive inhalers that have not seen generic competition, as well as epinephrine autoinjectors and other drugs.
The FTC push is part of a wider crackdown on the way patent thickets can be built up over decades to squelch generic drug competition. Currently, patents listed in the FDA’s Orange Book are not vetted by the FDA or any outside experts to see if they comply with applicable laws or regulations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.